Eli Lilly and Co
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 378
- Registration Number
- NCT00734604
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1202
- Registration Number
- NCT00734474
- Locations
- π¨π³
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Biological: IMC-A12 (cixutumumab)Drug: tamoxifenDrug: AnastrozoleDrug: LetrozoleDrug: ExemestaneDrug: Fulvestrant
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 93
- Registration Number
- NCT00728949
- Locations
- πΊπΈ
ImClone Investigational Site, Nashville, Tennessee, United States
Fibromyalgia Health Outcome Study on Cost of Treatments
- Conditions
- Fibromyalgia
- Interventions
- Drug: Treatment for Fibromyalgia
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1700
- Registration Number
- NCT00725101
- Locations
- π΅π·
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Isabel, Puerto Rico
Study of Ramucirumab in Ovarian Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
- Interventions
- Biological: Ramucirumab
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00721162
- Locations
- π¬π§
ImClone Investigational Site, Sutton, United Kingdom
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
- Conditions
- Waldenstrom's MacroglobulinemiaMultiple Myeloma
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT00718419
- Locations
- π«π·
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nimes, France
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
- Conditions
- Essential ThrombocythemiaAcute Myeloid Leukemia
- Interventions
- Drug: LY573636-sodium
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT00718159
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
- Conditions
- DyslexiaAttention Deficit Hyperactivity Disorder
- Interventions
- Drug: PlaceboDrug: Atomoxetine
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 110
- Registration Number
- NCT00716274
- Locations
- πΊπΈ
Yale University School of Medicine, New Haven, Connecticut, United States
A Study for Participants With Metastatic Renal Cell Carcinoma
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 17
- Registration Number
- NCT00709995
- Locations
- π΅π±
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1144
- Registration Number
- NCT00703326
- Locations
- π¬π§
ImClone Investigational Site, Nottingham, United Kingdom